Oppenheimer Reiterates Relmada Therapeutics Perform Rating, Removes $7 Price Target
Oppenheimer Reiterates Relmada Therapeutics Perform Rating, Removes $7 Price Target
奧本海默重申雷爾馬達治療執行評級,刪除 7 美元目標價格
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊